• Nintedanib (BIBF 1120) in ATRX-Deficient Glioma

  2026-09-23

  Use Nintedanib to test how broad VEGFR, FGFR, and PDGFR blockade affects angiogenic signaling and cancer-cell responses. An ATRX-focused workflow helps distinguish a promising pathway-level hypothesis from evidence that has not yet established Nintedanib as an ATRX-selective glioma treatment.

• (-)-Blebbistatin and Heat-Responsive Cardiac Biology

  2026-09-23

  The discovery that HCN4 couples temperature to cardiac pacemaker activity creates a compelling framework for testing how membrane excitability interacts with cytoskeletal force. This thought-leadership guide positions (-)-Blebbistatin as a reversible non-muscle myosin II inhibitor for separating actomyosin-dependent mechanics from HCN4-driven electrical responses, while emphasizing controls, translational boundaries, and assay strategy.

• Phenylhydrazones as ER Proteostasis Regulators

  2026-09-22

  The preprint identifies a covalent interaction between the phenylhydrazone compound AA263 and a subset of endoplasmic reticulum protein disulfide isomerases, providing a mechanistic basis for ATF6-linked proteostasis remodeling. Its next-generation analogs improve ATF6 activation and show functional correction of disease-associated protein folding and trafficking defects, although the findings remain pre-peer-review and require broader validation.

• Nigericin sodium salt: Practical Assay Setup

  2026-09-22

  Nigericin sodium salt is a potassium ionophore for controlled K+/H+ exchange, ion-gradient perturbation, and cytoplasmic pH regulation studies. This guide covers solvent handling, short-exposure assay design, platelet workflows, and QC while emphasizing that the compound is for research use only and is unsuitable for water- or DMSO-based preparations, diagnosis, or treatment.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-21

  The reference study shows that ATRX-deficient high-grade glioma cells are more vulnerable than ATRX-proficient counterparts to several receptor tyrosine kinase and PDGFR inhibitors. Its most actionable implication is that ATRX status should be considered when interpreting RTK-inhibitor trials and when designing combinations with temozolomide.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-09-21

  The reference study identifies ATRX deficiency as a potential determinant of response to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination experiments further show that ATRX status may influence temozolomide-based treatment responses, although clinical validation is still required.

• Letrozole: A Causal Framework for Endocrine Assays

  2026-09-20

  Letrozole is a reversible non-steroidal aromatase inhibitor for dissecting estrogen-dependent biology. This guide presents a causal assay framework that separates target engagement, estrogen receptor alpha downregulation, endocrine feedback, and downstream phenotypes.

• Nintedanib (BIBF 1120) Experimental Workflow

  2026-09-19

  Build reproducible angiogenesis, glioma, and fibrosis assays with Nintedanib, a VEGFR/FGFR/PDGFR inhibitor suited to pathway-focused experiments. This workflow connects ATRX-stratified glioma screening with practical dosing, formulation, endpoint selection, and troubleshooting guidance.

• CGK733 in TP53-Mutant GBM Ferroptosis Studies

  2026-09-18

  CGK733 can be evaluated as a hypothesis-generating perturbation in TP53-mutant glioblastoma ferroptosis research. This article translates recent iron-homeostasis findings into a disciplined assay strategy while separating established evidence from experimental inference.

• HCN4 Heat Sensing Sets Cardiac Pacemaker Rate

  2026-09-18

  The reference study identifies an M407/Y409 motif in the HCN4 S4–S5 linker as a temperature-sensing element that couples heat to sinoatrial node excitability and heart-rate acceleration. Through modeling, mutagenesis, cellular electrophysiology, and genetically modified mice, the authors show that this motif is also required for cAMP-dependent HCN4 activation, revealing an unexpected hierarchy in channel gating.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-09-17

  Pladevall-Morera and colleagues identified a genotype-linked vulnerability in high-grade glioma: ATRX-deficient cells were more sensitive to multi-targeted receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient comparators. The study also found increased toxicity when RTK inhibition was combined with temozolomide, supporting ATRX status as a useful stratification variable for glioma drug development rather than as a standalone treatment biomarker.

• (-)-Blebbistatin for Cardiac Contractility Studies

  2026-09-17

  (-)-Blebbistatin provides reversible, selective inhibition of non-muscle myosin II for separating cytoskeletal mechanics from electrical activity. Paired with panoramic opto-electrical mapping, it supports practical studies of actomyosin force, cardiac contractility, cell migration, and tissue-level signal propagation.

• Bismuth Subsalicylate: From GI Biology to Translation

  2026-09-16

  A translational framework for using Bismuth Subsalicylate to connect prostaglandin pathway biology with annexin V-based membrane readouts, while controlling for insolubility, particulate artifacts, and nonspecific cell injury in gastrointestinal research.

• Bismuth Subsalicylate: GI Research Workflows

  2026-09-16

  Build reproducible gastrointestinal disorder research workflows around Bismuth Subsalicylate while separating nominal dosing, suspension behavior, inflammation pathway modulation, and membrane-level outcomes. A practical annexin V workflow adds single-cell resolution without assuming that phosphatidylserine exposure proves a direct apoptotic mechanism.

• H 89 2HCl: Mapping PKA in Bone Cells

  2026-09-15

  H 89 2HCl enables mechanistic interrogation of cAMP-dependent protein kinase inhibition in osteoclast models. This article explains how to use it to test the dopamine–cAMP/PKA/CREB hypothesis while separating pathway causality from off-target kinase effects.

7905 records 1/527 page Next 12345 下5页 Last page